CSTL Q2 2022 Earnings — Castle Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

CSTLCastle Biosciences, Inc.

$805M

Q2 2022 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$35M+53.1% YoY

Gross Profit

$27M77.9% margin

Operating Income

-$24M-69.9% margin

Net Income

-$2M-4.7% margin

EPS (Diluted)

$-0.06

QoQ Revenue Growth

+29.7%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$10M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$458M

Total Liabilities

$37M

Stockholders' Equity

$422M

Cash & Equivalents

$273M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$35M	$23M	+53.1%
Gross Profit	$27M	$19M	+42.4%
Operating Income	-$24M	-$9M	-176.6%
Net Income	-$2M	-$9M	+81.3%

Revenue Segments

Dermatologic

$32M92%

Service, Other

$3M8%